obinutuzumab + lenalidomide + methylprednisolone

**Obinutuzumab + lenalidomide + methylprednisolone** is an investigational chemotherapy-free co-administration regimen evaluated by the University of California, San Diego for Richter's syndrome. It combines obinutuzumab, a type II anti-CD20 monoclonal antibody that depletes malignant B cells; lenalidomide, a cereblon-binding immunomodulatory agent; and high-dose methylprednisolone, a glucocorticoid receptor agonist with lympholytic and immunosuppressive effects. The regimen was studied in the Phase 1 trial NCT03113695 to assess safety, tolerability, and antitumor activity in Richter's syndrome. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03113695))

Other names

obinutuzumab + high-dose methylprednisolone + lenalidomideobinutuzumab + HDMP + lenalidomideobinutuzumab, high-dose methylprednisolone, and lenalidomide